InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Duncan Gregory Scott, Chief Executive Officer. Insider active across 2 companies, notably Virios Therapeutics, Inc.. Cumulatively, 5 disclosures have been published. Split: 3 buys · 0 sell. Total volume traded: €85k. Activity tracked since 21 December 2021. The latest transaction was filed on 16 September 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations5 total
13,333 shares@ US$8.32Common StockSEC:0001213900-25-089216:0
25,000 shares0Common StockSEC:0001213900-25-005667:0
25,000 shares@ US$1.249826.3% of flowCommon StockSEC:0001415889-23-012375:0
Ideal exit: 13 May 2024 (T+270)
7,500 shares@ US$4.5239.3% of flowCommon StockSEC:0001415889-22-005567:0
Ideal exit: 17 Feb 2023 (T+270)
5,000 shares@ US$5.52330.3% of flowCommon StockSEC:0001415889-21-006172:0
Ideal exit: 17 Sept 2022 (T+270)
5 of 5 declarations
About Duncan Gregory Scott
Gregory Scott Duncan is the Chief Executive Officer of Virios Therapeutics, Inc. He oversees the company's operations, which focuses on developing therapeutic treatments. Gregory Scott Duncan is responsible for the overall strategy and direction of the company, ensuring that research and development objectives are met.
